Quinine Sulphate BP: Bulk API for Pharma Companies

 A naturally occurring crystalline alkaloid salt obtained from the Cinchona tree bark, Quinine Sulphate has detailed quality specifications dictated by the BP Compendial Monograph relating to its identity, physical characteristics, potency and purity. Where manufacturers of pharmaceuticals purchase Quinine Sulphate based on this Compendial Monograph, they obtain an active raw material suitable for efficient formulation and safety.

Technical Profile and Key Specifications

To meet modern formulation standards, high-purity Quinine Sulphate BP must adhere to clear technical criteria:

• Chemical Name: Quinine sulfate dihydrate

• CAS Registry Number: 6119-70-1 (dihydrate) / 8047-15-2 (anhydrous basis)

• Molecular Formula: $(C_{20}H_{24}N_2O_2)_2 \cdot H_2SO_4 \cdot 2H_2O$

• Appearance: Fine, white or almost white, odorless, silky crystalline needles or powder.

• Solubility: Sparingly soluble in water, freely soluble in boiling water, sparingly soluble in ethanol (96%), and practically insoluble in ether.

• Assay Range: 99.0% to 101.0% (calculated on an anhydrous basis).

• Specific Optical Rotation: $-235^\circ$ to $-245^\circ$ (calculated on an anhydrous basis).

• Impurities & Organic Volatile Impurities: strictly controlled limits on related cinchona alkaloids (dihydroquinine, cinchonidine, quinidine) via High-Performance Liquid Chromatography (HPLC).

Difference Between Quinine Sulphate BP, USP, and EP 

While BP, USP, and EP monographs have the fundamental tests specified in their respective test procedures for Quinine Sulphate, slight differences occur in acceptance limits for individual impurities, limits for Loss on drying, and procedures and specifications for residual solvents testing. Procurement teams need to specifically purchase the BP grade only when supplying the respective territories like UK, Commonwealth, Middle East, part of Asia and Africa for regulatory filing.

Therapeutic Applications and Formulation Utility 

Quinine Sulphate BP is a major API in number of therapeutic categories. This has a unique pharmacological way that is considered useful for pharmaceutical formulation.

Treatment of Plasmodium falciparum Malaria

Quinine Sulphate is a classic blood schizonticide. It acts by interfering with the parasite's ability to digest hemoglobin inside red blood cells, leading to toxic accumulation of heme within the parasite.

• Uncomplicated Falciparum Malaria: Often used as a second-line or combination therapy when first-line artemisinin-based combination therapies (ACTs) are contraindicated or unavailable.

• Severe Malaria Management: Step-down oral therapy after initial intravenous quinine infusion treatments.

• Drug Resistance Control: Valuable in managing multi-drug resistant strains of Plasmodium falciparum due to its lower rate of acquired resistance development compared to synthetic antimalarials.

Management of Nocturnal Leg Cramps 

Other indications that are commonly prescribed using non-approved use or standardized strengths of formulation (200 to 300mg tablets) involve lowering the incidence and severity of night time leg cramps:

Action: Motor end-plate responsivity is reduced while the electrical excitability of the muscle end-plate is modified, thereby increasing muscle refractory period.

Clinical Consideration: There is the strict requirement for the batches to exhibit similar API purity from batch to batch so that side-effects are reduced such as cinchonisrn or thrombocytopenia, which further ensures BP monograph requirements have been fulfilled.

Critical Quality Attributes (CQAs) in API Production 

Particle Size Distribution (PSD): Having tight control of the PSD by micronization during tableting / capsule filling insures that blended profiles and dissolution profile are also maintained tightly.

Impurity profiling: Controlling low levels of by-product secondary alkaloids (dihydroquinine, cinchonidine) is necessary for limits defined by BP specifications.

Hydration State control: The specific dihydrate crystal structure need to be maintained for proper policy change.

Endotoxin and Bioburden checks. Necessary when API is used for critical care products or specialty formulations.

Regulatory Compliance, Documentation, and Packaging 

When sourcing for Quinine Sulphate BP as a bulk vendor. Supply Chain managers must ensure thorough regulatory support to ease in drug master file (DMF) filing and obtaining market approvals..

Required regulatory dossiers

Certificate of Analysis (CoA)-Each batch of product comes with an independent CoA showing all BP parameters.
Drug Master File (DMF)-This includes both an open and closed part available for health authority submissions.
CGMP Certificate - a written declaration confirming the manufacturing site adhere to Current Good Manufacturing Practices regulations.
CEP / COS (Certificate of Suitability) - streamlines market authorization procedures with various European countries as well as international markets.
Stability Data – studies performed for accelerated and long-term stability according to guidelines set in ICH (Zone II, Zone IVa and Zone IVb).
Residual Solvent Declarations – stating compliance to the ICH Q3C regulation.

Commercial Packaging & Bulk Storage Guidelines 

Quinine Sulphate BP is photoluminescent and, on exposure to direct sunlight or humid conditions, gradually changes color to lighter tones. 

Normal Commercial Pack: Double food-grade anti-static polyethylene (PE) bags, sealed with anti-tamper ties Inner Container and High density polyethylene HDPE or fiber Drums (net wt. $25K g$ or $50K g$) Outer Container 

Recommended Storage: Store in tight containers (light-resistant) in a controlled room temperature ($15^{0}C-30^{0}C$) in dry space without heat or direct light. 

Normally shelf life of product is 36 - 60 Months under the unbroken conditions at recommended storagae.

Superior product quality necessitates the procurement of Reliable Quinine Sulphate BP from a dependable API supplier. In order to achieve the same with regards to tablet manufacture, high-quality Quinine Sulphate BP is extremely crucial. This high purity active ingredient plays an integral role in producing antimalarial drugs and several other medical treatments.

Working with a regulatory compliant API supplier assures that strict compliance with British Pharmacopoeia standards will be met along with high batch-to-batch variability in consistency.

They will provide complete regulatory support from development to marketing. Develop a sturdy supply chain which allows for easy manufacture of your tablet and fulfillment of the global demand.

Conclusion : 

We are engaged in the steady supply and distribution of the drug substance of Quinine Sulphate BP for pharmaceutical businesses looking to establish an upstream reliance of the substance. Maintaining a sustained level of quality with regard to the substance supplied will provide pharmaceutical companies with a quality dependent source for these requirements, with the reliability of being bulk and professional to service needs. Quality relationships and servicing will facilitate lasting supply relationships in global API sourcing.